Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CAPOX + sintilimab + bevacizumab as first-line therapy for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200059975Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, bevacizumab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-limiting toxicity incidence and Objective response rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
sintilimabbevacizumabcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200059975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059975.